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Abstract: Quetiapine has demonstrated efﬁ  cacy in schizophrenia, bipolar disorder and in the 
treatment of speciﬁ  c symptom clusters such as agitation and sleep problems in mood disorders. 
In this review, randomized controlled studies demonstrating efﬁ  cacy, safety and tolerability 
of quetiapine in major depressive disorder (MDD) and general anxiety disorder (GAD) are 
evaluated. The results show that quetiapine monotherapy and quetiapine augmentation of 
antidepressant treatment in MDD and GAD are efﬁ  cacious for short-term and maintenance 
treatment at a dose range between 50 and 300 mg/day. Quetiapine appears to have a speciﬁ  c but 
overall mild side-effect proﬁ  le, though, some adverse effects such as sedation and somnolence 
may lead to withdrawal from treatment in some patients. Overall, the available evidence suggests 
that there is a signiﬁ  cant role for quetiapine in the treatment of MDD and GAD.
Keywords: quetiapine, major depressive disorders, general anxiety disorder, randomized 
controlled studies, adverse effects
Introduction
The enhancement of treatment response of major depressive disorder (MDD) and general 
anxiety disorder (GAD) is a major goal in clinical research and patient care. Clinical trials 
indicate that over 50% of depressed patients show an inadequate response to antidepres-
sant therapy (Fava and Davidson 1996; Ferrier 1999) and that incomplete recovery from 
MDD increases the risk of both chronicity and recurrence. Recovery, which involves a 
complete remission of symptoms and a return to baseline psychosocial function, should be 
the goal of therapy (Rush and Trivedi 1995; Nierenberg and Wright 1999). Poor response 
to adequate antidepressant treatment has been termed ‘treatment resistant depression’ 
(TRD) (Ananth 1998). Although there is lack of agreement on a formal deﬁ  nition of 
TRD, one that is often cited deﬁ  nes it as a failure of response to at least two trials of 
antidepressant medication, at an adequate dose and duration from at least two different 
classes (Ananth 1998). Issues such as adherence, missed diagnosis of psychotic depres-
sion, bipolar disorder, or co-morbid anxiety should be investigated in patients who have 
not responded to initial therapeutic strategies (Kennedy and Lam 2003).
Beyond ensuring optimal use of the index antidepressant, treatment strategies for 
TRD include switching to another antidepressant, and augmentation or combination 
with two or more agents. In patients with TRD, adding or augmenting with lithium, 
tri-iodothyronine or atypical antipsychotics have demonstrated beneﬁ  ts (Kennedy 
and Lam 2003). Augmentation with atypical antipsychotics, including risperidone, 
olanzapine, ziprasidone, and quetiapine, has shown promising results in terms of 
improving remission rates (Shelton and Papakostas 2008).
The atypical antipsychotic quetiapine has shown efﬁ  cacy in the treatment 
of positive and negative symptoms in schizophrenia (Srisurapanont et al 2004). Neuropsychiatric Disease and Treatment 2008:4(6) 1182
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Quetiapine has more recently gained attention as a 
clinically useful treatment option in patients with bipolar 
affective disorder (Calabrese et al 2005; Thase et al 2006; 
Keating and Robinson 2007; Weisler et al 2008b) and 
major depression (Todder et al 2006; Baune et al 2007) 
due to its mood stabilizing effects (Ghaemi and Katzow 
1999; Vieta 2005).
Quetiapine and its major active human plasma metabolite, 
N-desalkyl quetiapine, has shown in vitro antagonistic 
activity on multiple brain neurotransmitter receptors 
and in particular on serotonergic (5HT2A), noradrenergic 
(α1-adrenoreceptor) and the noradrenergic transporter, thus 
having a positive inﬂ  uence on mood (Arango and Bernardo 
2005). With its anti-dopaminergic properties (D1, D2), 
quetiapine is considered to evolve impact on motor activity, 
eg, on agitation in depression (Todder et al 2006; Dannlowski 
et al in press).
Quetiapine has demonstrated clinical efficacy in 
the past few years for clinical indications ranging from 
bipolar disorder (Berk and Dodd 2005; Calabrese et al 
2005; Croissant et al 2006) and treatment of behavioral 
disturbances in dementia (Savaskan et al 2006) to the 
management of substance dependence disorders (Sattar 
et al 2004; Croissant et al 2006; Hanley and Kenna 2008). 
Moreover, positive effects of quetipiane on sleep architecture 
and sleep recovery in healthy subjects (Cohrs et al 2004) as 
well as its sleep promoting effects in depression (Todder 
et al 2006) and bipolar disorder (Sokolski and Denson 2003), 
have been demonstrated in recent years. Preliminary evidence 
suggests a role for quetiapine in managing TRD (Sagud et al 
2006; Doree et al 2007) and anxiety symptoms in bipolar 
depression (Hirschfeld et al 2006).
These recently published studies support the view 
that quetiapine has a broad range of clinical use in mood 
disorders including major depression and symptom clus-
ters such as agitation and sleep deterioration in mood and 
anxiety disorders. Although a number of reviews have 
examined the efﬁ  cacy of quetiapine in bipolar disorder 
(Dando and Keating 2005; Keating and Robinson 2007; 
Khazaal et al 2007; Shelton and Papakostas 2008), there 
is no review of controlled randomized studies in MDD 
and GAD available to date. Most recent accumulating data 
on the effects of quetiapine in MDD and anxiety disorder 
have been substantially derived from small open-label 
uncontrolled studies (Philip et al 2008), since data from 
randomized controlled studies were not available, such as 
for quetiapine as augmentation therapy for depression or 
anxiety (Nemeroff 2005).
A review of randomized and controlled studies focusing 
on the efﬁ  cacy, safety and tolerability, and patient outcomes, 
such as quality of life, patient satisfaction and adherence for 
quetiapine treatment of MDD and GAD, would be of use 
to the clinical and research orientated reader. This review 
evaluates the recently available randomized controlled 
studies on quetiapine in MDD and GAD (Philip et al 2008) 
and goes beyond the mostly open-label studies published on 
quetiapine in TRD or unipolar depression (Nemeroff 2005; 
Gao et al 2006; Doree et al 2007).
Method
Studies were identiﬁ  ed using searches of Pubmed/Medline. 
Searches were conducted by cross-referencing the term 
‘major depressive disorder (MDD)’ or ‘general anxiety 
disorder (GAD)’ with ‘quetiapine’. Restriction to the 
minimum criteria of double-blind, randomized, placebo 
controlled studies published in the English language was 
used. These searches were then repeated using EMBase 
and the Cochrane databases as well. We also searched 
the abstracts of major psychiatric meetings held since 
2000 (American Psychiatric Association; New Clinical 
Drug Evaluation Unit of the National Institutes of Mental 
Health; American College of Neuropsychopharmacology; 
European College of Neuropsychopharmacology; 
Collegium Internationale Neuropsychopharmacologicum; 
Society of Biological Psychiatry, World Federation of 
Societies of Biological Psychiatry; World Psychiatric 
Association).
Results
Pharmacology of immediate 
and extended release quetiapine
Rationale and mode of action
The receptor-binding properties of quetiapine are complex, 
and it appears unlikely that a single mechanism could 
explain the observed inﬂ  uence on major depression and 
anxiety disorders (Saller and Salama 1993; Richelson and 
Souder 2000).
The active metabolite of quetipiane, N-desalkyl quetiapine, 
has a high afﬁ  nity for the histamine H1 receptor and moderate 
afﬁ  nities for the norepinephrine reuptake transporter (NET), 
the serotonin 5-HT1A, 5-HT1E, 5-HT2A, 5-HT2B, 5-HT7 recep-
tors, the α1B-adrenergic receptor, and the M1, M3, and M5 
muscarinic receptors. The compound had low afﬁ  nities for 
the 5-HT1D, 5-HT2C, 5-HT3, 5-HT5, 5-HT6, α1A, α2A, α2B, 
α2C, H2, M2, M4, and dopamine D1, D2, D3, and D4 receptors. Neuropsychiatric Disease and Treatment 2008:4(6) 1183
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N-Desalkyl quetiapine potently inhibited human NE 
transporter about 100-fold more potent than quetiapine itself. 
N-desalkyl quetiapine was also 10-fold more potent and more 
efﬁ  cacious than quetiapine at the 5-HT1A receptor. N-Desalkyl 
quetiapine was an antagonist at 5-HT2A, 5-HT2B, 5-HT2C, 
α1A, α1D, α2A, α2C, H1, M1, M3, and M5 receptors. A moderate 
afﬁ  nity for the norepinephrine reuptake inhibitor transporter 
(NET) and partial 5HT1A agonism, which are considered 
the possible reason for quetiapine’s antidepressant effects 
as investigated in mouse experiment (Jensen et al 2008). 
The extent to which the N-desalkyl quetiapine metabolite 
contributes to the pharmacological activity of quetiapine in 
humans is not known.
In pre-clinical tests predictive of extrapyramidal symptoms 
(EPS), quetiapine is unlike standard antipsychotics and has 
an atypical proﬁ  le. Quetiapine demonstrates selectivity for 
the limbic system by producing depolarisation blockade 
of the mesolimbic but not the nigrostriatal dopamine-
containing neurones following chronic administration. The 
results of these tests predict that quetiapine should have 
minimal EPS liability, may also have a lower liability to 
produce tardive dyskinesia (data on ﬁ  le, AstraZeneca 
Pharmaceuticals, Wilmington, DE, USA). The production 
of sustained elevations in prolactin, which is considered a 
feature of atypical agents, is not evident during quetiapine 
administration unlike most other antipsychotics (Atmaca et al 
2002). However, a study by Alexiadis et al (2002) indicates 
that oral administration of quetiapine was associated with 
a marked but transient increase in serum prolactin levels. 
A recent study investigating the relationship between 
increased prolactin levels and sexual dysfunction showed 
that in this 6-week randomized double-blind trial, higher 
serum prolactin level was related to greater impairment of 
sexual functioning in male outpatients who were treated with 
risperidone. This effect was not seen in patient treated with 
quetiapine (Nakonezny et al 2007).
Pharmacodynamics
Quetiapine and the human plasma metabolite, N-desalkyl 
quetiapine, interact with a broad range of neurotransmitter 
receptors. Quetiapine, like clozapine, is an effective 
antipsychotic at lower D2 receptor occupancy which may 
account for its very low risk of EPS and prolactin elevation 
(Kapur et al 2000; Tauscher-Wisniewski et al 2002). 
Quetiapine and N-desalkyl quetiapine exhibit afﬁ  nity for 
brain serotonin (5HT2) and dopamine D1 and D2 receptors. 
It is this combination of receptor antagonism with a higher 
selectivity for 5HT2 relative to D2 receptors which is believed 
to contribute to the clinical antipsychotic properties and 
low EPS liability of quetiapine (data on ﬁ  le, AstraZeneca 
Pharmaceuticals, Wilmington, DE, USA).
Pharmacokinetics: absorption, metabolism, 
distribution, elimination
Following oral administration quetiapine is extensively 
metabolized by the liver. Steady state peak molar concen-
trations of the active metabolite N-desalkyl quetiapine are 
35% of that observed for quetiapine. The pharmacokinetics 
of quetiapine and N-desalkyl quetiapine are linear across the 
approved dosage range.
At daily doses of 450 to 600 mg the D2 occupancy 
of quetipiane fumarate peaks within 2 to 3 hours of its 
administration (45%–60%) and quickly declines to less than 
30% by 12 hours after the last oral dose (Gefvert et al 1998; 
Kapur et al 2000). Its rapid pharmacokinetics properties 
necessitate twice-daily dosing, which could lower adherence 
to the treatment (Iskedjian et al 2002; Diaz et al 2004). 
However, quetiapine immediate release is clinically also 
used at once-daily doses. The extended release formulation 
(XR) of quetiapine fumarate was developed with the goal 
of achieving similar efﬁ  cacy and using a once-daily dosing 
regimen (Kahn et al 2007; Moller et al 2008). Compared 
to the immediate-release (IR) formulation (DeVane and 
Nemeroff 2001), the XR formulation shows a more gradual 
rise in plasma level (tmax = 6 hours) and a slower decline over 
a 24-hour period (t1/2 = 7 hours (data on ﬁ  le, AstraZeneca 
Pharmaceuticals, Wilmington, DE, USA).
Dose-proportional pharmacokinetics is displayed for 
doses of quetiapine XR of up to 800 mg administered once 
daily. The maximum plasma concentration (Cmax) and the 
area under the plasma concentration-time curve (AUC) for 
quetiapine XR when administered once daily are comparable 
to those achieved for the same total daily dose of immediate-
release quetiapine fumarate administered twice daily.
Quetiapine is extensively metabolized by the liver and 
is approximately 83% bound to plasma proteins. In vitro 
investigations established that CYP3A4 is likely to be the 
primary enzyme responsible for cytochrome P450 mediated 
metabolism of quetiapine. N-desalkyl quetiapine is primarily 
formed and eliminated via CYP3A4. CYP2D6 and CYP2C9 
are also involved in quetiapine metabolism.
Quetiapine and several of its metabolites (including 
N-desalkyl quetiapine) are weak to modest inhibitors 
of human cytochrome P450 3A4, 2C19, 2D6, 1A2 and 
2C9 activities in vitro. From animal studies it appears 
that quetiapine can induce cytochrome P450 enzymes. Neuropsychiatric Disease and Treatment 2008:4(6) 1184
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In a speciﬁ  c interaction study in psychotic patients, however, 
no increase in the cytochrome P450 activity was found after 
administration of quetiapine. The elimination half-lives of 
quetiapine and N-desalkyl quetiapine are approximately 
7 and 12 hours respectively (data on ﬁ  le, AstraZeneca 
Pharmaceuticals, Wilmington, DE, USA).
Efﬁ  cacy studies of quetiapine 
XR in MDD and GAD
Efﬁ  cacy of quetiapine XR in MDD
The efﬁ  cacy results of quetiapine XR in MDD are presented 
in Table 1. The six completed double-blind, randomized, 
placebo-controlled trials with quetipiane XR in MDD 
can be grouped into 1) monotherapy studies, 2) adjunct 
studies and 3) maintenance studies.
Monotherapy studies of quetiapine XR in MDD
In a 6-week, multicenter, double-blind, randomized, parallel-
group, placebo-controlled study evaluating the efﬁ  cacy of 
Quetiapine XR (50, 150, and 300 mg/day) as monotherapy 
in the treatment of patients with MDD, the primary endpoint 
was improvement on the Montgomery-Asberg Depression 
Rating Scale (MADRS) between randomization and week 6 
(Weisler et al 2008a). A total of 723 adult patients were 
randomized: 182, 178, 179, and 184 to quetiapine XR 50, 
150, 300 mg/day, and placebo, respectively. Mean scores at 
baseline were: MADRS 30.9, 30.9, 30.6, and 30.5; Hamilton 
Depression rating scale (HAM-D) 25.6, 25.5, 25.7, and 
25.5; HAM-A 19.6, 19.4, 19.7, and 19.3, respectively. At 
week 6, all quetiapine XR groups signiﬁ  cantly reduced mean 
MADRS score vs placebo (–11.07): –13.56 (p  0.05) for 
50 mg, –14.50 (p  0.001) for 150 mg, –14.18 (p  0.01) 
for 300 mg.
In a second trial, this time a 10-week, double-blind, 
randomized, parallel-group, placebo-controlled study, the 
authors assessed the efﬁ  cacy of quetiapine XR (150/300 mg/
day) as monotherapy for the treatment of MDD using a ﬁ  xed-
dose regime (El-Khalili et al 2008a). A total of 310 patients 
were randomized to double-blind treatment: 154 quetiapine 
XR, 156 placebo. The primary endpoint was change from 
randomization to week 8 in MADRS total score. At week 8, 
quetiapine XR signiﬁ  cantly reduced mean MADRS score vs 
placebo (–16.49 vs –13.10; p  0.01). MADRS response 
rates were signiﬁ  cantly greater at week 8 for quetiapine 
XR vs placebo (61.9% vs 48.0%; p  0.05).
In a third trial using a similar study design (8-week 
study, multicenter, double-blind, randomized, parallel-group, 
placebo-controlled) Montgomery et al (2008) investigated 
the efficacy of quetiapine XR (150 and 300 mg/day) as 
monotherapy in the treatment of MDD utilizing an active control 
group of duloxetine 60 mg/day (Montgomery et al 2008). In this 
study, 612 adult patients were randomized to receive quetiapine 
XR 150 mg/day (n = 152), quetiapine 300 mg/day (n = 152), 
duloxetine 60 mg/day (n = 151) and placebo (n = 157). The 
primary endpoint was change in MADRS total score baseline 
at week 6. Secondary variables included baseline to week 6 
change in HAM-D total scores and Item 1 (depressed mood) 
scores. Mean MADRS total score (overall baseline mean, 
30.15) was signiﬁ  cantly reduced at week 6 the quetiapine XR 
150 mg/day, quetiapine 300 mg/day and the duloxetine groups 
compared to the placebo group (–14.81, –15.29, –14.64, –11.18, 
respectively; p  0.001). At week 6, mean HAM-D total scores 
(overall baseline mean, 25.25) were signiﬁ  cantly reduced 
vs placebo (–10.26) in the quetiapine XR 150 mg/day and 
300 mg/day groups (–13.12, –14.02, respectively, p  0.001) 
and duloxetine (–12.37, p  0.05). Mean HAM-D Item 1 scores 
(overall baseline mean, 3.03) were signiﬁ  cantly reduced vs 
placebo (–1.07) by quetiapine XR 150 mg/day, 300 mg/day 
(–1.49, –1.56, respectively, p  0.001) and duloxetine (–1.53, 
p  0.001). Both MADRS response and remission rates 
were signiﬁ  cantly higher in quetiapine XR 300 mg/day and 
duloxetine as compared to placebo (Table 1). Quetiapine XR 
150 mg/day showed robust effects on remission rates in the 
study by Montgomery et al (2008).
Maintenance treatment in MDD with quetiapine
XR monotherapy
The efﬁ  cacy of quetiapine XR (50–300 mg/day) monotherapy 
was investigated in a maintenance treatment of patients 
with MDD in a 52-week, multicenter, double-blind, 
randomized-withdrawal, parallel-group, placebo-controlled 
study following an open-label stabilisation period (Datto 
et al 2008). Primary endpoint was the efﬁ  cacy of quetiapine 
XR vs placebo in increasing time from randomization to 
depressed event as assessed by predeﬁ  ned criteria. A total 
of 787 patients were randomized to double-blind treatment: 
391 quetiapine XR; 385 placebo. The risk of a depressed 
event was signiﬁ  cantly reduced for quetiapine XR vs pla-
cebo (implying increased time to the event): HR = 0.34 
(0.25, 0.46); p  0.0001. Over the study period, a total of 55 
(14.2%) quetiapine XR-treated and 132 (34.4%) placebo-
treated patients experienced a depressed event.
Adjunctive treatment with quetiapine XR
Two randomized placebo controlled studies are reported, 
which examined the adjuvant effects of quetiapine. Neuropsychiatric Disease and Treatment 2008:4(6) 1185
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Quetiapine in MDD and GAD
In an 8-week, multicenter, double-blind, randomized, 
parallel-group, placebo-controlled study the efﬁ  cacy of 
Quetiapine XR (150 and 300 mg/day) in combination 
with an antidepressant for the treatment of MDD and an 
inadequate response to previous antidepressant treatment 
was evaluated (El-Khalili et al 2008b). Patients received 
and antidepressant (SSRI/SNRI/TCA/bupropion) and 
either quetiapine XR 150 mg/day, 300 mg/day or placebo. 
The primary endpoint in this study was total change in 
MADRS score between randomization and week 6. A total 
of 446 patients were randomized: 148, 150, and 148 to 
quetiapine XR 150 mg/day, 300 mg/day and placebo, 
respectively. Mean baseline scores were: MADRS: 27.2, 
27.6, and 27.6; HAM-D 24.0, 24.0, and 24.2, respectively. 
Quetiapine XR 300 mg/day + AD showed signiﬁ  cant advan-
tage vs placebo + AD for: 1) change in MADRS total score 
at week 6 (–14.70 vs –11.7; p  0.01); 2) improvement 
in MADRS from week 1 onwards; 3) response (58.9% vs 
46.2%; p  0.05); 4) remission (42.5% vs 24.5%; p  0.01). 
For quetiapine XR 150 mg/day + AD improvements in these 
variables were not signiﬁ  cantly different vs placebo.
The second adjunct study using a 6-week, double-blind, 
randomized, parallel-group, placebo-controlled study design 
evaluated the efﬁ  cacy of quetiapine XR (150/300 mg/day) in 
combination with an antidepressant in the treatment of MDD 
in patients with an inadequate response to an antidepressant 
monotherapy. Previous antidepressant treatment was 
maintained. The primary endpoint was the change in MADRS 
total score between baseline and week 6. As a result, mean 
change in MADRS total score (overall baseline mean, 28.4) 
from baseline to week 6 was signiﬁ  cant (p  0.01) for 
quetiapine XR 150 mg/day (–15.26) and 300 mg/day (–14.94) 
vs placebo (–12.21). Results on response and remission were 
inconclusive (see Table 1).
Efﬁ  cacy of quetiapine XR in GAD
The efﬁ  cacy results of quetiapine XR in GAD are presented 
in Table 2. While the three controlled published studies 
investigate quetiapine XR monotherapy in GAD, one 
of the controlled studies used an active control group of 
paroxetine.
Monotherapy studies of short-term and long-term 
treatment with quetiapine XR in GAD
The ﬁ  rst study is a 10-week, randomized, double-blind, 
parallel-group, placebo-controlled trial evaluating the efﬁ  cacy 
of quetiapine XR (50, 150, and 300 mg/day) compared 
with placebo in the treatment of GAD (Khan et al 2008). 
The primary endpoint was total score change on the Hamilton 
Anxiety rating scale (HAM-A) from baseline to week 8. 
Secondary endpoints included: HAM-A total score change 
from baseline to Week 1; HAM-A response and remission 
rates at week 8. A total of 951 patients were randomized: 
quetiapine XR 50 mg/day (n = 234); 150 mg/day (n = 241); 
300 mg/day (n = 241) or placebo (n = 235). HAM-A total 
score mean change from baseline (overall baseline mean 
24.6) to week 8 was signiﬁ  cantly greater for 50 mg/day 
(–13.3, p  0.001) and 150 mg/day (–13.5, p  0.001) but 
not 300 mg/day (–11.9, p = 0.24) vs placebo (–11.1). HAM-A 
response rates (week 8) were signiﬁ  cantly higher for 50 mg/
day (60.3%, p  0.05) and 150 mg/day (61.5%, p  0.05) 
but not 300 mg/day (54.9%, p = 0.37) vs placebo (50.7%). 
HAM-A remission rates (week 8) were signiﬁ  cantly higher 
for 150 mg/day vs placebo (37.2% vs 27.6%, p  0.05); 
50 mg/day and 300 mg/day remission rates were 36.1% 
(p = 0.08) and 28.6% (p = 0.96), respectively.
In a second study, the long-term efﬁ  cacy of quetiapine XR 
monotherapy following an open-label 1 period (50–300 mg/
day) in GAD was evaluated in a 52-week, double-blind, 
randomized-withdrawal, parallel-group, placebo-controlled 
clinical trial (Katzman et al 2008). Participants received 
quetiapine XR 4-8-week open-label followed by 12- to 
18-week stabilization. Eligible patients (HAM-A 12; 
MADRS  16; CGI-S  3) were randomized to quetiapine 
XR or placebo at last open-label visit dose, which 
subsequently could be adjusted to 50, 150, or 300 mg/day as 
clinically indicated. The primary objective was to evaluate 
the efﬁ  cacy of quetiapine XR vs placebo in increasing 
time from randomization to an anxiety event according to 
predeﬁ  ned criteria. Of the 433 patients who were randomized 
to double-blind treatment, half received quetiapine XR (216) 
and placebo (217). The risk of an event was signiﬁ  cantly 
reduced for quetiapine XR vs placebo (implying increased 
time to the event): HR = 0.19 (0.12, 0.31); p  0.0001. 
Twenty-two quetiapine XR patients experienced an anxiety 
event which was a significantly lower percentage than 
the 84 placebo-treated patients who experienced an anxiety 
event (10.2% vs 38.9%, p  0.001). The study concluded 
that quetiapine XR monotherapy signiﬁ  cantly reduced risk 
of relapse of anxiety events in patients with GAD.
Adjunctive treatment with quetiapine XR
This controlled trial was a 10-week, randomized, double-
blind, parallel-group, placebo-controlled, active-controlled 
study evaluating the efﬁ  cacy of quetiapine XR (50 and 
150 mg/day) compared with placebo for the treatment Neuropsychiatric Disease and Treatment 2008:4(6) 1188
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Quetiapine in MDD and GAD
of GAD (Chouinard et al 2008). This study included an 
active control group of paroxetine 20 mg/day. The primary 
endpoint employed in this study was the HAM-A total 
score change from baseline to week 8 and the secondary 
endpoint considered response and remission criteria. In total, 
873 patients were randomized to quetiapine XR 50 mg/day 
(n = 221), 150 mg/day (n = 218), paroxetine 20 mg/day 
(n = 217), or placebo (n = 217). Mean HAM-A total score 
(baseline mean, 26.98) was signiﬁ  cantly decreased at day 4 
by both quetiapine XR doses (p  0.05) and at week 8 by 
quetiapine XR 50 mg/day (–13.95, p  0.05), 150 mg/day 
(–15.96, p  0.001), and paroxetine (–14.45, p  0.01) vs 
placebo (–12.30). Quetiapine XR at both doses as well 
as paroxetine showed signiﬁ  cantly higher response and 
remission rates (except quetiapine XR 50 mg for remission 
rates) as presented in Table 2.
Safety, tolerability, and adherence 
in treatment with quetiapine
It has been demonstrated that quetiapine monotherapy is well 
tolerated for the treatment of bipolar depression (BOLDER 
study) (Calabrese et al 2005). In this particular study, extra-
pyramidal symptoms were assessed with the Simpson-Angus 
Rating Scale (Simpson and Angus 1970), and akathisia was 
assessed with the Barnes Rating Scale for Drug-Induced 
Akathisia (Barnes 1989). The most common side effects 
of quetiapine included dry mouth, sedation, somnolence, 
dizziness, and constipation. The most common side effects 
leading to withdrawal from the study were sedation and 
somnolence, with most discontinuations occurring within 
the ﬁ  rst week. The most common reasons for withdrawal 
were related to adverse events in the quetiapine groups 
(300/600 mg/day) (26.1% and 16.0%) and lack of efﬁ  cacy 
in the placebo group (13.3%) (Calabrese et al 2005).
Of importance, changes in weight observed were 
relatively small and did not result in withdrawal from the 
study (Calabrese et al 2005). More speciﬁ  cally, during the 
quetiapine monotherapy study performed by Weisler et al 
patients in the quetiapine XR 50 (n = 178), 150 (n = 168), 
and 300 mg/day (n = 176) groups experienced a mean 
weight change of +0.6 kg, +0.9 kg, and 1.0 kg, respectively, 
while patients in the placebo group (n = 178) experienced a 
mean weight change of +0.6 kg. The proportion of patients 
experiencing 7% increase in weight was 0.6%, 3.6%, 
4.5%, and 1.1% for 50, 150, 300 mg/day quetiapine XR, and 
placebo, respectively (Weisler et al 2008a).
Quetiapine treatment was not associated with treatment-
emergent mania. Furthermore, adverse events considered 
extra-pyramidal symptoms were present in 8.9% of the 
600 mg/day group, 6.7% of the 300 mg/day group, and 2.2% 
of the placebo group; discontinuation rates for extra-pyramidal 
symptoms were 2.8%, 1.1%, and 0.6%, respectively.
The side effect proﬁ  le of quetiapine was assessed in 
detail in studies by Datto et al (2008) and Montgomery 
et al (2008) assessing the efﬁ  cacy of quetiapine XR on 
MDD. While Table 3 shows that quetiapine XR was more 
frequently related to dry mouth, sedation, and somnolence 
than duloxetine and placebo in an 8-week trial, results on 
adverse events presented in Table 4 indicate that those typical 
side effects are similar in pattern but slightly less common 
in long-term treatment of up to 52 weeks with quetiapine. 
Interestingly, the adverse events reported do not indicate a 
dose-response relationship for quetiapine XR 150 mg and 
300 mg. In all of the above reported studies evaluating the 
efﬁ  cacy of quetiapine XR in MDD and GAD no changes 
on ECG parameters between treatment and placebo were 
reported.
Impact of quetiapine XR on quality of life
Health-related quality of life measures obtained in 
randomized-controlled trials are reported for some of the GAD 
studies. In the studies by Chouinard and by Katzmann quality 
of life was measured using the Quality of Life Enjoyment and 
Satisfaction Questionnaire (Q-LES-Q). After adjustment for 
multiplicity (quetiapine groups only), signiﬁ  cant increases in 
Q-LES-Q percent maximum possible total score were seen 
with quetiapine XR 150 mg and paroxetine compared with 
placebo at week 8 (13.19, 10.85, and 7.44, respectively) 
(Chouinard et al 2008) (Figure 1). Similarly, in the study 
by Katzmann et al (in press) health-related quality of life 
enjoyment and satisfaction was better with quetiapine XR 
compared with the placebo group.
Conclusions
While quetiapine has demonstrated efﬁ  cacy in schizophrenia 
and bipolar disorder as well as in the treatment of speciﬁ  c 
symptoms clusters such as agitation and sleep problems in 
mood disorders, most recent randomized controlled studies 
show efﬁ  cacy, safety and tolerability of quetiapine in major 
depressive disorder and general anxiety disorder, as evaluated 
in this review. The efﬁ  cacious application of quetiapine 
in MDD and GAD ranges from quetiapine monotherapy 
to adjunctive therapy with antidepressants for short-
term and maintenance treatment at a dose range between 
50–300 mg/day. The dual action of quetipiane and its active 
metabolite N-desalkyl quetiapine on the norepinephrine Neuropsychiatric Disease and Treatment 2008:4(6) 1190
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Table 3 Most common adverse events (AEs) (5% in any group) during the active treatment period (safety population)
AE, n (%) Placebo (n = 157) Quetiapine XR 150 mg/day 
(n = 152)
Quetiapine XR 300 mg/day 
(n = 152)
Duloxetine 
(n = 179)
Dry mouth 14 (8.9) 51 (33.6) 58 (38.2) 28 (18.8)
Sedation 8 (5.1) 59 (38.8) 56 (36.8) 24 (16.1)
Somnolence 11 (7.0) 37 (24.3) 41 (27.0) 19 (12.8)
Dizziness 17 (10.8) 22 (14.5) 29 (19.1) 25 (16.8)
Headache 16 (10.2) 16 (10.5) 14 (9.2) 27 (18.1)
Constipation 10 (6.4) 9 (5.9) 13 (8.6) 17 (11.4)
Irritability 7 (4.5) 2 (1.3) 9 (5.9) 0
Dyspepsia 5 (3.2) 6 (3.9) 8 (5.3) 8 (5.4)
Fatigue 0 4 (2.6) 8 (5.3) 10 (6.7)
Nausea 15 (9.6) 16 (10.5) 8 (5.3) 54 (36.2)
Vision blurred 3 (1.9) 8 (5.3) 8 (5.3) 4 (2.7)
Increased appetite 3 (1.9) 9 (5.9) 6 (3.9) 3 (2.0)
Diarrhea 10 (6.4) 7 (4.6) 4 (2.6) 16 (10.7)
Upper respiratory 
tract infection
11 (7.0) 3 (2.0) 4 (2.6) 6 (4.0)
Abnormal dreams 1 (0.6) 10 (6.6) 3 (2.0) 4 (2.7)
Pollakiuria 2 (1.3) 5 (3.3) 3 (2.0) 8 (5.4)
Insomnia 11 (7.0) 2 (1.3) 2 (1.3) 22 (14.8)
Decreased appetite 1 (0.6) 5 (3.3) 0 8 (5.4)
Hyperhidrosis 1 (0.6) 0 0 11 (7.4)
reuptake inhibitor transporter (NET) and the 5HT1A 
receptor is considered the possible reason for quetiapine’s 
antidepressant effects.
Quetiapine appears to have a speciﬁ  c but overall mild 
side-effect proﬁ  le. Some adverse effects such as sedation and 
somnolence may however lead to withdrawal from treatment 
in some patients. Despite the often beneﬁ  cial sedative effects 
of quetiapine on clinically relevant sleep problems in psy-
chiatric patients, quetipaine is not recommended soley as a 
sleeping agent. Overall, the most recently available evidence 
on quetiapine suggests that it can play a signiﬁ  cant role in 
the management of MDD and GAD.
Table 4 Most common adverse events (AEs) (5%) occurring in any group during the open-label and randomization treatment phases 
(safety population)
Preferred term, n (%) Open-label phase Randomized phase
Quetiapine XR (n = 1078) Placebo (n = 385) Quetiapine XR (n = 391)
Dry mouth 259 (24.0) 6 (1.6) 14 (3.6)
Somnolence 362 (33.6) 0 15 (3.8)
Sedation 218 (20.2) 1 (0.3) 10 (2.6)
Dizziness 142 (13.2) 17 (4.4) 26 (6.6)
Fatigue 152 (14.1) 10 (2.6) 17 (4.3)
Weight increased 68 (6.3) 6 (1.6) 38 (9.7)
Headache 93 (8.6) 44 (11.4) 27 (6.9)
Constipation 70 (6.5) 1 (0.3) 8 (2.0)
Nausea 62 (5.8) 38 (9.9) 14 (3.6)
Irritability 93 (8.6) 12 (3.1) 3 (0.8)
Nasopharyngitis 23 (2.1) 25 (6.5) 28 (7.2)
Insomnia 37 (3.4) 57 (14.8) 22 (5.6)
Diarrhea 24 (2.2) 26 (6.8) 21 (5.4)Neuropsychiatric Disease and Treatment 2008:4(6) 1191
Quetiapine in MDD and GAD
*
*
12
14
10
8
6
4
2                 
0          
I
m
p
r
o
v
e
m
e
n
t
 
(
%
)
Placebo Quetiapine XR 50 mg Quetiapine XR 150 mg Paroxetine
*P ≤ 0.05 vs placebo; N.S. = not significant from placebo 
N.S.
N.S.
Figure 1 Improvement of quality of life measures in patients with generalized anxiety disorder.
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